Literature DB >> 18927459

Extension of the thrombolytic time window with minocycline in experimental stroke.

Yoshihiro Murata1, Anna Rosell, Robert H Scannevin, Kenneth J Rhodes, Xiaoying Wang, Eng H Lo.   

Abstract

BACKGROUND AND
PURPOSE: Thrombolysis with tPA is the only FDA-approved therapy for acute ischemic stroke. But its widespread application remains limited by narrow treatment time windows and the related risks of cerebral hemorrhage. In this study, we ask whether minocycline can prevent tPA-associated cerebral hemorrhage and extend the reperfusion window in an experimental stroke model in rats.
METHODS: Spontaneously hypertensive rats were subjected to embolic focal ischemia using homologous clots and treated with: saline at 1 hour; early tPA at 1 hour, delayed tPA at 6 hours; minocycline at 4 hours; combined minocycline at 4 hours plus tPA at 6 hours. Infarct volumes and hemorrhagic transformation were quantified at 24 hours. Gelatin zymography was used to measure blood levels of circulating matrix metalloproteinase-9 (MMP-9).
RESULTS: Early 1-hour thrombolysis restored perfusion and reduced infarction. Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion. Combining minocycline with delayed 6-hour tPA decreased plasma MMP-9 levels, reduced infarction, and ameliorated brain hemorrhage. Blood levels of MMP-9 were also significantly correlated with volumes of infarction and hemorrhage.
CONCLUSIONS: Combination therapy with minocycline may extend tPA treatment time windows in ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18927459      PMCID: PMC3705574          DOI: 10.1161/STROKEAHA.108.514026

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  39 in total

1.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.

Authors:  G J del Zoppo; K Poeck; M S Pessin; S M Wolpert; A J Furlan; A Ferbert; M J Alberts; J A Zivin; L Wechsler; O Busse
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

2.  A new rat model of thrombotic focal cerebral ischemia.

Authors:  Z Zhang; R L Zhang; Q Jiang; S B Raman; L Cantwell; M Chopp
Journal:  J Cereb Blood Flow Metab       Date:  1997-02       Impact factor: 6.200

3.  Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion.

Authors:  G F Hamann; Y Okada; G J del Zoppo
Journal:  J Cereb Blood Flow Metab       Date:  1996-11       Impact factor: 6.200

4.  Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.

Authors:  Yi Yang; Eduardo Y Estrada; Jeffrey F Thompson; Wenlan Liu; Gary A Rosenberg
Journal:  J Cereb Blood Flow Metab       Date:  2006-07-19       Impact factor: 6.200

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats.

Authors:  Carles Justicia; Julián Panés; Sònia Solé; Alvaro Cervera; Ramon Deulofeu; Angel Chamorro; Anna M Planas
Journal:  J Cereb Blood Flow Metab       Date:  2003-12       Impact factor: 6.200

7.  Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.

Authors:  David P Stirling; Kourosh Khodarahmi; Jie Liu; Lowell T McPhail; Christopher B McBride; John D Steeves; Matt S Ramer; Wolfram Tetzlaff
Journal:  J Neurosci       Date:  2004-03-03       Impact factor: 6.167

8.  Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury.

Authors:  Yang D Teng; Howard Choi; Renna C Onario; Shan Zhu; Federico C Desilets; Shoumin Lan; Eric J Woodard; Evan Y Snyder; Marc E Eichler; Robert M Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

9.  Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion.

Authors:  G F Hamann; Y Okada; R Fitridge; G J del Zoppo
Journal:  Stroke       Date:  1995-11       Impact factor: 7.914

10.  Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats.

Authors:  Lin Xu; Susan C Fagan; Jennifer L Waller; David Edwards; Cesar V Borlongan; Jianqing Zheng; William D Hill; Giora Feuerstein; David C Hess
Journal:  BMC Neurol       Date:  2004-04-26       Impact factor: 2.474

View more
  97 in total

Review 1.  Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.

Authors:  Wei Wang; Mingchang Li; Qianxue Chen; Jian Wang
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

Review 2.  Evaluation of combination therapy in animal models of cerebral ischemia.

Authors:  Victoria E O'Collins; Malcolm R Macleod; Geoffrey A Donnan; David W Howells
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-01       Impact factor: 6.200

Review 3.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

Review 4.  The neurovascular unit and combination treatment strategies for stroke.

Authors:  Li Zhang; Zheng Gang Zhang; Michael Chopp
Journal:  Trends Pharmacol Sci       Date:  2012-05-16       Impact factor: 14.819

Review 5.  Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing.

Authors:  Victoria E O'Collins; Malcolm R Macleod; Susan F Cox; Leena Van Raay; Elena Aleksoska; Geoffrey A Donnan; David W Howells
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-27       Impact factor: 6.200

6.  Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction.

Authors:  Ann C Rice; Victoria L Chiou; Sarah B Zuckoff; Steven M Shapiro
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

Review 7.  Neurovascular matrix metalloproteinases and the blood-brain barrier.

Authors:  Ji Hae Seo; Shuzhen Guo; Josephine Lok; Deepti Navaratna; Michael J Whalen; Kyu-Won Kim; Eng H Lo
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Astrogliosis: a target for intervention in intracerebral hemorrhage?

Authors:  Sangeetha Sukumari-Ramesh; Cargill H Alleyne; Krishnan M Dhandapani
Journal:  Transl Stroke Res       Date:  2012-04-14       Impact factor: 6.829

Review 9.  Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease.

Authors:  Kota Kurisu; Jong Youl Kim; Jesung You; Midori A Yenari
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

10.  Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.

Authors:  Xiang Fan; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2013-02-19       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.